Автор |
KUMAOKA, SOICHI |
Автор |
TAKATANI, OSAMU |
Автор |
YOSHIDA, MINORU |
Автор |
MIURA, SHIGETO |
Автор |
TAKAO, TETSUTO |
Автор |
HAMANAKA, YÜJI |
Автор |
IZUO, MASARU |
Автор |
OKADA, TADAKAZU |
Дата выпуска |
1974 |
dc.description |
A new orally active anti-estrogenic steroid, 2α,3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S) was given to 41 advanced breast cancer patients. Most patients were given a daily dose of 20 mg. The study was preliminary and not a controlled trial using an already proven androgenic steroid. The remission rate on giving this compound to advanced breast cancer was 11/41 or 26.8% and the average duration of the remission was 10.5 months.Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relatively often seen as virilizing side effects. No unfavorable effects on the hematopoietic organs, the liver or on calcium metabolism were recognized in the study. |
Формат |
application.pdf |
Издатель |
Oxford University Press |
Копирайт |
© 1974 JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
Тема |
ORIGINALS |
Название |
2α,3α-Epithio-5α-androstan-17β-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial— |
Тип |
research-article |
Electronic ISSN |
1465-3621 |
Print ISSN |
0368-2811 |
Журнал |
Japanese Journal of Clinical Oncology |
Том |
4 |
Первая страница |
65 |
Последняя страница |
68 |
Аффилиация |
KUMAOKA SOICHI; National Cancer Center Research Institute |
Аффилиация |
TAKATANI OSAMU; National Cancer Center Hospital |
Аффилиация |
YOSHIDA MINORU; Aichi Cancer Center Hospital |
Аффилиация |
MIURA SHIGETO; Aichi Cancer Center Hospital |
Аффилиация |
TAKAO TETSUTO; First Department of Surgery, Osaka University Medical School |
Аффилиация |
HAMANAKA YÜJI; First Department of Surgery, Osaka University Medical School |
Аффилиация |
IZUO MASARU; Department of Surgery, Gunma University, School of Medicine |
Аффилиация |
OKADA TADAKAZU; Department of Surgery, Gunma University, School of Medicine |
Выпуск |
1 |